Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
HUTCHMED (China) Limited (HK:0013)
HKEX:0013
RESEARCH TOOLSreports
Holding HK:0013?
Track your performance easily
0013 Stock Chart & Stats
Day’s RangeHK$0 - HK$0
52-Week RangeHK$19.00 - HK$35.90
Previous CloseHK$27.3
Volume2.96M
Average Volume (3M)4.30M
Market Cap
HK$23.79B
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.41
Next Earnings
Feb 27, 2025EPS Estimate
-HK$0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.38
Shares Outstanding871,359,720
10 Day Avg. Volume4,530,492
30 Day Avg. Volume4,303,446
Standard Deviation0.20
R-Squared0.26
Alpha0.00732
Financial Highlights & Ratios
Price to Book (P/B)6.66
Price to Sales (P/S)3.98
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$39.07Price Target Upside43.13% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
HUTCHMED (China) Limited News
PremiumCompany Announcements
HUTCHMED Expands Cancer Treatment Market with Japan Launch
PremiumCompany Announcements
HUTCHMED China Announces Diverse Board Leadership
PremiumCompany Announcements
HUTCHMED Appoints Experienced Director to BoardPremiumCompany Announcements
HUTCHMED to Present Promising Clinical Data in 2024
PremiumCompany Announcements
HUTCHMED Receives Milestone Payment from TakedaOptions Prices
Currently, No data available
---
Ownership Overview
1.11% Insiders
1.80% Mutual Funds
― Other Institutional Investors
94.81% Public Companies and
Individual Investors
0013 FAQ
What was HUTCHMED (China) Limited’s price range in the past 12 months?
HUTCHMED (China) Limited lowest stock price was HK$19.00 and its highest was HK$35.90 in the past 12 months.
What is HUTCHMED (China) Limited’s market cap?
Currently, no data Available
When is HUTCHMED (China) Limited’s upcoming earnings report date?
HUTCHMED (China) Limited’s upcoming earnings report date is Feb 27, 2025 which is in 96 days.
How were HUTCHMED (China) Limited’s earnings last quarter?
HUTCHMED (China) Limited released its earnings results on Jul 31, 2024. The company reported HK$0.233 earnings per share for the quarter, beating the consensus estimate of -HK$0.607 by HK$0.84.
Is HUTCHMED (China) Limited overvalued?
According to Wall Street analysts HUTCHMED (China) Limited’s price is currently Undervalued.
Does HUTCHMED (China) Limited pay dividends?
HUTCHMED (China) Limited does not currently pay dividends.
What is HUTCHMED (China) Limited’s EPS estimate?
HUTCHMED (China) Limited’s EPS estimate is -HK$0.07.
How many shares outstanding does HUTCHMED (China) Limited have?
HUTCHMED (China) Limited has 871,561,950 shares outstanding.
What happened to HUTCHMED (China) Limited’s price movement after its last earnings report?
HUTCHMED (China) Limited reported an EPS of HK$0.233 in its last earnings report, beating expectations of -HK$0.607. Following the earnings report the stock price went up 5.769%.
Which hedge fund is a major shareholder of HUTCHMED (China) Limited?
Currently, no hedge funds are holding shares in HK:0013
---
HUTCHMED (China) Limited Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
HK$39.07 (43.13% Upside)
HK$39.07 (43.13% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-3.63%
12-Months-Change
Fundamentals
Return on Equity
-5.61%
Trailing 12-Months
Asset Growth
-2.27%
Trailing 12-Months
Company Description
HUTCHMED (China) Limited
Hutchison China Meditech is an innovative biopharmaceutical company engaged in the discovery, global development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Its reportable segments include the innovation platform and commercial platform. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The commercial platform includes a prescription drugs business and a consumer health business for over-the-counter drugs.
---
0013 Stock 12 Month Forecast
Average Price Target
HK$39.07
▲(43.13% Upside)
Technical Analysis
HUTCHMED (China) Limited
―
ANGLE plc
―
AstraZeneca
―
Scancell Holdings
―
ImmuPharma
―
Best Analysts Covering 0013
1 Year
1 Year Success Rate
3/4 ratings generated profit
1 Year Average Return
+8.08%
reiterated a buy rating 4 months ago
Copying Jill Wu's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +8.08% per trade.
---